Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)
Conditions
Interventions
Enzastaurin
Placebo
Locations
1
United States
Aytu BioPharma
Englewood, Colorado, United States
Start Date
January 1, 2025
Primary Completion Date
June 1, 2025
Completion Date
March 1, 2027
Last Updated
March 8, 2024
Lead Sponsor
Aytu BioPharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions